Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones

RE104 is the focus of Reunion Neuroscience program updates for 2026, including FDA-aligned registrational planning for postpartum depression (PPD) and planned new Phase 3 activity. For PPD, Reunion reports completing an FDA End-of-Phase 2 meeting supported by Phase 2 RECONNECT results, and expects that one additional Phase 3 trial could complete the pivotal studies needed for potential registration. Reunion also expects Phase 3 initiation in 2026 and notes FDA feedback allowing enrollment of actively breastfeeding women, who would return to breastfeeding the same day of treatment after discharge. For other indications, Reunion is enrolling a Phase 2 REKINDLE trial of RE104 for adjustment disorder (AjD), expecting topline data in 1Q 2027 after completing enrollment by year-end. For generalized anxiety disorder (GAD), Reunion plans to initiate a Phase 2 RECLAIM trial in 1Q 2026. The release also describes RE245 as a non-psychedelic serotonergic neuroplasticity candidate targeting 5HT2A-mediated neuroplasticity without hallucinations or cardiotoxicity, with IND filing planned for 2026 and Phase 1 in 2027.